ABSI · Absci Corp
$10.77
+0.63 (+6.21%)
At close · Sep 30
Return incl. dividend (before tax)
Market Cap
$1.64B
Shares
171.61M
Volume · Sep 30
5.43M
Avg daily vol (3M)
3.49M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$10.77
Open$10.36
Day$10.04–10.99
52W close$2.30–11.62
Avg vol 30d3.6M
Short int37.3M · 21.7% float · 14.4d
Short vol52%
Last earningsAug 11, 2026
DataJul 2021–Sep 2026
Filing10-Q · Aug 11
Up next
Next earnings call
Nov 19, 2026
Est · unconfirmed
· in 7 wks
filed Aug 11, 2026
call held Aug 11, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$1.56M
Trailing 12 months
Net income (TTM)
−$121.08M
Trailing 12 months
Revenue growth YoY
-46.4%
Year over year
Operating margin
-8,084.5%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+23.4%
Year over year · more shares
Price change (1Y)
+241.4%
Trailing year
Short interest
21.7%
Latest settlement · 14.4 days to cover
AI Brief
Q2 FY26 earnings call · Aug 11, 2026
Q2 FY26
TL;DR. Absci reported positive interim Phase 1 ABS-201 data supporting a potential two-to-three injection dosing regimen, completed a $100 million financing including a $40 million Eli Lilly strategic investment, extended its cash runway into the second half of 2028, and announced the upcoming initiation of an ABS-201 Phase 2 endometriosis trial in Q4 2026.
Bullish
- + Positive interim Phase 1 ABS-201 data suggest favorable safety and a half-life of at least 65 days, supporting a potential two-to-three injection regimen over six months.
- + Absci completed a $100 million underwritten offering, including a $40 million strategic equity investment from Eli Lilly.
- + Cash runway extended into the second half of 2028 following the financing.
- + Eli Lilly joined Absci's Endometriosis Advisory Board as part of the new partnership.
- + Absci anticipates initiating a Phase 2 trial of ABS-201 in endometriosis in Q4 2026, with potential proof-of-concept data in 2H 2027.
- + Modeling supports greater than 90% sustained prolactin receptor occupancy with two-to-three doses over six months, which management believes is a key driver of efficacy.
Bearish
- − Net loss widened to $33.2 million in Q2 2026 from $30.6 million in Q2 2025.
- − R&D expenses increased to $22.6 million from $20.5 million year-over-year.
- − Revenue declined to $0.3 million from $0.6 million year-over-year.
- − Durability of ABS-201 efficacy will not be demonstrated at the 13-week or 26-week interim readouts.
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.53
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+86%
above
Price vs 50-day avg
+21%
above
RSI (14)
62
neutral
MACD trend
Positive
52-week position
91%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+22%
trailing
6-month return
+265%
trailing
YTD return
+209%
this year
Relative strength
+253%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $9 › 200d $6 — 50d above 200d
Institutional flow
Accumulating
+22% holders QoQ · +52 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
21.71% of float · ▲ +1.3% MoM · 14.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
200 holders — near 3-yr high, broad support
Squeeze score
76
high risk · 0–100
Fundamentals
Revenue growth
−21%
Y/Y
EPS growth
+11%
Y/Y
Free cash flow
$-94.0M
Balance sheet
$37.2M
net cash
Quant / Vol
risk profile
Volatility
107%
annualized · 1-yr
Max drawdown
−54%
past year
ATR
7.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+86%
Bullish
Price vs 50-day avg
+21%
Bullish
RSI (14)
62
Neutral
MACD trend
Positive
Bullish
52-week position
91%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $9 › 200d $6 — 50d above 200d
Institutional flow
Accumulating
+22% holders QoQ · +52 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
21.71% of float · ▲ +1.3% MoM · 14.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
200 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $2
Now $11 · 91%
Range high $12
vs 200-day avg +86%
vs 50-day avg +21%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ABSI
this stock
Absci Corp
|
$1.64B | +208.6% | -20.7% | — | 21.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +15.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -1.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +553.0% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ABSI | +10.5% | +21.8% | +265.1% | +19.1% | +208.6% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | +11.2% | +21.7% | +252.9% | +19.7% | +196.8% |